
Ask a doctor about a prescription for RABEPRAZOL AUROVITAS SPAIN 20 mg GASTRO-RESISTANT TABLETS
Patient Information: Summary of Product Characteristics
Rabeprazol Aurovitas Spain 20mg gastro-resistant EFG tablets
Rabeprazole sodium
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Rabeprazol Aurovitas Spain contains the active ingredient rabeprazole sodium. Rabeprazole belongs to a class of medicines known as “proton pump inhibitors” (PPIs), which work by reducing the amount of acid produced by the stomach.
Rabeprazole is used for the treatment of:
Do not takeRabeprazol Aurovitas Spain
Do not take rabeprazole if you are in any of the above situations. If you are not sure, consult your doctor or pharmacist before taking rabeprazole.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Rabeprazol Aurovitas Spain.
If you are unsure about any of the above, consult your doctor or pharmacist before taking rabeprazole.
During treatment with rabeprazole, kidney inflammation may occur. The signs and symptoms include: decreased urine volume or blood in the urine and/or hypersensitivity reactions such as fever, skin rash, and joint stiffness. You should report these signs to your doctor.
Children
Rabeprazol should not be given to children.
If you experience severe diarrhea (watery or bloody) with symptoms such as fever, abdominal pain, or sensitivity, stop taking rabeprazole and see your doctor immediately.
Taking a proton pump inhibitor like rabeprazole, especially for more than one year, may slightly increase the risk of fracture in the hip, wrist, or spine. Inform your doctor if you have osteoporosis or are taking corticosteroids (which can increase the risk of osteoporosis).
Other medicines and Rabeprazol Aurovitas Spain
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
If you are unsure about any of the above, consult your doctor or pharmacist before taking rabeprazole.
Pregnancy, breast-feeding, and fertility
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel drowsy while taking rabeprazole. If this happens, do not drive or use tools or machines.
Rabeprazol Aurovitas Spain contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially “sodium-free”.
Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Taking this medicine
Adults and elderly
For “gastroesophageal reflux disease” (GERD)
Treatment of moderate to severe symptoms (symptomatic GERD)
Treatment of more severe symptoms (erosive or ulcerative GERD)
Long-term treatment of symptoms (maintenance GERD)
For stomach ulcers (peptic ulcers)
For intestinal ulcers (duodenal ulcers)
For ulcers caused by H. Pylori infection and to prevent recurrence
For more information on the other medicines used to treat H. pylori, read the package leaflet for each of them.
Zollinger-Ellison syndrome where there is an excess of acid in the stomach
If you are on long-term treatment, you will need to see your doctor at regular intervals for a review of your dose and symptoms.
Patients with liver problems. You should consult your doctor, who will be particularly careful when starting and during treatment with rabeprazole.
If you take more Rabeprazol Aurovitas Spain than you should
If you take more rabeprazole than your doctor has prescribed, consult a doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Rabeprazol Aurovitas Spain
If you stop taking Rabeprazol Aurovitas Spain
Relief of symptoms usually occurs before the ulcer is completely healed. It is important that you do not stop treatment until your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking rabeprazole and contact your doctor immediately if you notice any of the following side effects – you may need urgent medical treatment:
These side effects are rare (may affect up to 1 in 1,000 people):
These side effects are very rare (may affect up to 1 in 10,000 people):
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from the available data):
Reporting of side effects:
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Blister packs: Do not store above 25°C. Store in the outer packaging to protect from moisture.
Bottles: Do not store above 25°C. Keep the container tightly closed to protect from moisture.
Do not use this medicine after the expiry date which is stated on the carton, blister, and label after EXP. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Rabeprazol Aurovitas Spain
Appearance of the Product and Container Content
Rabeprazol Aurovitas Spain 20 mg gastro-resistant EFG tablets: Yellow, biconvex, and elliptical film-coated tablets.
Container sizes:
Blister packs: 7, 14, 20, 28, 30, 56, 60, 98, 100, and 120 tablets.
Plastic bottles with a desiccant: 30, 100, and 250 tablets.
Plastic bottles with an integrated desiccant: 30, 100, and 250 tablets.
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer
Coripharma ehf.
Reykjavikurvegur 78
IS-220 Hafnarfjörður
Iceland
or
Puren Pharma GmbH & Co. KG,
Willy-Brandt-Allee 2,
81829 Munich,
Germany
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Germany: | Rabeprazol PUREN 20 mg gastro-resistant tablets |
Spain: | Rabeprazol Aurovitas Spain 20 mg gastro-resistant EFG tablets |
Netherlands: | Rabeprazolnatrium Auro 20 mg, gastro-resistant tablets |
Portugal: | Rabeprazol Aurovitas |
Date of the Last Revision of this Leaflet: October 2022
Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of RABEPRAZOL AUROVITAS SPAIN 20 mg GASTRO-RESISTANT TABLETS in January, 2026 is around 24.37 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for RABEPRAZOL AUROVITAS SPAIN 20 mg GASTRO-RESISTANT TABLETS – subject to medical assessment and local rules.